Cargando…
Sensitivity and Resistance of Oncogenic RAS-Driven Tumors to Dual MEK and ERK Inhibition
SIMPLE SUMMARY: Mutations in RAS-family genes frequently cause different types of human cancers. Inhibitors of the MEK (mitogen-activated protein kinase) and ERK (extracellular signal-regulated kinase) protein kinases that function downstream of RAS proteins have shown some clinical benefits when us...
Autores principales: | Catalano, Antonella, Adlesic, Mojca, Kaltenbacher, Thorsten, Klar, Rhena F. U., Albers, Joachim, Seidel, Philipp, Brandt, Laura P., Hejhal, Tomas, Busenhart, Philipp, Röhner, Niklas, Zodel, Kyra, Fritsch, Kornelia, Wild, Peter J., Duyster, Justus, Fritsch, Ralph, Brummer, Tilman, Frew, Ian J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8069437/ https://www.ncbi.nlm.nih.gov/pubmed/33924486 http://dx.doi.org/10.3390/cancers13081852 |
Ejemplares similares
-
Longitudinal analysis of cell-free mutated KRAS and CA 19–9 predicts survival following curative resection of pancreatic cancer
por: Hussung, Saskia, et al.
Publicado: (2021) -
Evidence of renal angiomyolipoma neoplastic stem cells arising from renal epithelial cells
por: Gonçalves, Ana Filipa, et al.
Publicado: (2017) -
Oncogenic Hras(G12V) expression plus knockdown of Cdkn2a using ecotropic lentiviral vectors induces high-grade endometrial stromal sarcoma
por: Brandt, Laura P., et al.
Publicado: (2017) -
Integrated Metabolomic and Transcriptomic Analysis of Modified Nucleosides for Biomarker Discovery in Clear Cell Renal Cell Carcinoma
por: Mohl, Daniel A., et al.
Publicado: (2023) -
Onco-immunomodulatory properties of pharmacological interference with RAS-RAF-MEK-ERK pathway hyperactivation
por: Avery, Thomas Yul, et al.
Publicado: (2022)